NanoViricides Inc. (NNVC) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

NanoViricides Inc. (NNVC)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

1.20

0.02 (1.69%)

At close: Jan 15, 2025, 3:59 PM

1.20

0.42%

After-hours Jan 15, 2025, 04:10 PM EST

undefined% (undefined)

Bid	1.18
Market Cap	17.14M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.76
PE Ratio (ttm)	-1.57
Forward PE	n/a
Analyst	Buy

Ask	1.21
Volume	338,822
Avg. Volume (20D)	290,550
Open	1.20
Previous Close	1.18
Day's Range	1.12 - 1.21
52-Week Range	1.01 - 3.59
Beta	undefined

About NNVC

NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Oct 26, 2005

Employees 7

Stock Exchange AMEX

Ticker Symbol NNVC

Website https://www.nanoviricides.com

Analyst Forecast

According to 1 analyst ratings, the average rating for NNVC stock is "Buy." The 12-month stock price forecast is $6.5, which is an increase of 443.93% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

3 months ago · Source

+5.19%

NanoViricides shares are trading higher after the ... Unlock content with Pro Subscription

6 months ago · Source

+4.05%

NanoViricides shares are trading higher after the company announced it discussed its development program for NV-387.

News

4 days ago · proactiveinvestors.com

NanoViricides CEO discusses NV-387's broad spectrum promise - ICYMI

NanoViricides (NYSE-A:NNVC) CEO Dr Anil Diwan joined Proactive to highlight the company's lead drug candidate NV-387, which is targeting multiple viral families by mimicking receptors essential for vi...

1 week ago · proactiveinvestors.com

NanoViricides highlights urgent need for broad-spectrum antiviral solutions amid viral threats

NanoViricides (NYSE-A:NNVC) has highlighted the growing need for innovative antiviral solutions amid rising concerns over multiple viral threats, including H5N1 bird flu, COVID-19, RSV, and human meta...

3 weeks ago · proactiveinvestors.com

NanoViricides sees NV-387 as a key defense against bird flu pandemic

NanoViricides (NYSE-A:NNVC) said it believes that its broad-spectrum antiviral candidate, NV-387, could be a critical tool in combating a potential bird flu pandemic caused by the H5N1 Influenza A vir...

1 month ago · proactiveinvestors.com

NanoViricides CEO highlights urgency of H5N1 preparedness as cases rise in North America

The rise of unexplained human cases of bird flu in North America means there is an urgent need for effective treatments that can withstand viral mutations. In this opinion article, Anil Diwan, CEO of ...

2 months ago · proactiveinvestors.com

NanoViricides pushes NV-387 to Phase II trials

NanoViricides (NYSE-A:NNVC) reported progress on its lead antiviral drug NV-387 and revealed plans to advance Phase II clinical trials for MPox and RSV. The Shelton, Connecticut-based company is waiti...